Escitalopram and QTc Prolongation Management

Baseline Risk Assessment

Obtain a baseline ECG before initiating escitalopram in all patients, particularly those with cardiac risk factors, as recommended by the American Thoracic Society 1, 2, 3
Measure QTc using Fridericia's formula, as this is the FDA-recommended correction method, with a normal QTc being <430 ms in males and <450 ms in females, according to the American College of Cardiology 4
Do not initiate escitalopram if baseline QTc >500 ms, as stated by the American Heart Association 5, 6, 7
Correct electrolyte abnormalities before starting treatment, maintaining potassium >4.0 mEq/L and normal magnesium levels, as advised by the European Respiratory Society 1, 2, 8

Avoid escitalopram in patients with baseline QTc >500 ms, history of torsades de pointes, congenital long QT syndrome, recent myocardial infarction or decompensated heart failure, and uncorrected hypokalemia or hypomagnesemia, as recommended by the American Heart Association 5, 6, 7, 9
Avoid combining escitalopram with other QT-prolonging medications, such as Class IA and III antiarrhythmics, antipsychotics, antiemetics, antibiotics, and tricyclic antidepressants, as advised by the American College of Cardiology 1, 2, 4, 10

Follow the ECG monitoring schedule, including baseline ECG before initiation, repeat ECG at 2 weeks after starting treatment, and repeat ECG after any dose increase or when adding any new QT-prolonging medication, as recommended by the American Thoracic Society 1, 2, 3, 4
Monitor electrolytes (potassium, magnesium) regularly, as advised by the European Respiratory Society 1, 2, 8

If QTc prolongation occurs during treatment, immediately discontinue escitalopram, administer 2g IV magnesium, correct all electrolyte abnormalities, review and discontinue all other QT-prolonging medications, and provide continuous cardiac monitoring until QTc returns to baseline, as recommended by the American College of Cardiology 4, 8, 10